Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- NCC, NCI of US Ink MOU on Joint Research, Academic Interchanges
May 20, 2014
- Chuikyo to Discuss Sharp Difference in NHI Prices of Identical Products Tenozet, Viread
May 16, 2014
- Government Says Xeplion Approval Reasonable
May 15, 2014
- Chuikyo OKs NHI Price Listing of SGLT-2 Inhibitors, New Point-Based Calculations Adopted from This Time
May 15, 2014
- MHLW to Report Two Remicade Biosimilars to PAFSC’s Second Committee on Drugs on May 26
May 15, 2014
- MHLW Sends FPMAJ Details of New Point-Based Calculations for New Drug Pricing
May 14, 2014
- PIC/S to Discuss Japan’s Accession at Upcoming Meeting in Rome; MHLW Anticipates Formal Approval
May 14, 2014
- PMDA Raises Caution about Concomitant Use of ACE Inhibitors and ARBs
May 13, 2014
- Pilot Program for Compassionate Access System Gets Underway with Sanofi’s Cabazitaxel
May 7, 2014
- Joint Panel of Health, Science Ministries Wraps Up Talks on Ethics Code for Epidemiological, Clinical Research
May 2, 2014
- Topical Ketoprofen Contraindicated in Later Pregnancy: MHLW Safety Information
May 2, 2014
- Point-Based Calculations for Premiums Will Improve Predictability, Says Creator
May 1, 2014
- PAFSC’s Second Committee Backs Approval of Janssen, Sanofi Prostate Cancer Drugs
May 1, 2014
- PAFSC’s First Committee Recommends Approval for SGLT-2 Inhibitor Canaglu
April 30, 2014
- Kitasato Daiichi to Carry on with Delayed Quota in Flu Vaccine Project, but Slapped with Delinquency Charges
April 30, 2014
- Kaketsuken, Takeda Picked for Flu Vaccine Project to Fill BIKEN Quota
April 30, 2014
- MHLW Issues Notification Calling for Revision of Package Insert for Sanofi’s Benambax
April 30, 2014
- MHLW Bureaucrats Think Chuikyo Will Spurn Annual Drug Price Revisions, Again
April 28, 2014
- MHLW Should Present Its Own Proposal to Design Envisioned Mixed Care System: Panel Chair
April 28, 2014
- PMDA’s Preliminary Meetings, Face-to-Face Counseling Rise in FY2013
April 28, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…